Pharma Stability: Insights, Guidelines, and Expertise
While large pharmaceutical companies have long adopted Quality by Design (QbD) principles, small and mid-size enterprises (SMEs) often hesitate due to perceived complexity, costs, or lack of resources. However, QbD is not just for giants—it offers significant benefits even to lean teams. In fact, a strategic approach to QbD can improve product quality, regulatory compliance,…
Pharmaceutical regulatory agencies expect robust, science-based justifications for all aspects of a product’s lifecycle, especially in stability testing. By integrating Quality by Design (QbD) principles, companies can dramatically improve the quality, reliability, and acceptability of stability data included in regulatory filings. This article explores how QbD influences regulatory outcomes, drawing from ICH guidelines, FDA expectations,…
Read More “How QbD Improves Regulatory Outcomes in Stability Submissions” »
Incorporating Quality by Design (QbD) into long-term stability studies transforms stability testing from a reactive exercise to a proactive, science-based approach. This article explores best practices for implementing QbD in long-term stability studies across the product lifecycle, using a risk-based and data-driven framework aligned with ICH Q8 guidelines. 📘 Why Apply QbD to Long-Term Stability…
Read More “Best Practices in QbD Application for Long-Term Stability Studies” »